Boehringer Ingelheim has announced that the Spiriva Respimat tiotropium soft mist inhaler is now available in the United States. Patients will also still be able to purchase Spiriva Handihaler, the company said.
The FDA approved Spiriva Respimat for the treatment of COPD in September 2014.
Boehringer Ingelheim Pharmaceuticals VP, Clinical Development & Medical Affairs, Respiratory, Danny McBryan commented, “For 10 years, Spiriva HandiHaler has been a trusted maintenance therapy for patients with COPD, and Boehringer Ingelheim is proud to now offer another inhaler choice, Spiriva Respimat. Spiriva Respimat represents Boehringer Ingelheim’s continuing commitment to the COPD community to provide new treatment options.”
Read the Boehringer Ingelheim press release.
